Presentation on theme: "2/5/2010 – 1:00ameSlide – P6617 – MedImmune 8 x 4 Poster Template Objectives: Moxetumomab pasudotox (CAT-8015) is a recombinant immunotoxin composed of."— Presentation transcript:
2/5/2010 – 1:00ameSlide – P6617 – MedImmune 8 x 4 Poster Template Objectives: Moxetumomab pasudotox (CAT-8015) is a recombinant immunotoxin composed of a disulfide-stabilized anti-CD22 immunoglobulin variable domain and a truncated form of Pseudomonas exotoxin. It is currently being developed to treat CD22- expressing B-cell malignancies. The objective of this investigation was to develop a population pharmacokinetic (PK) -pharmacodynamic (PD) model to support the biocomparability assessment of Process 1 (P1) and Process 2 (P2) clinical materials in cynomolgus monkeys. Methods: In a GLP study male cynomolgus monkeys were randomized by baseline CD22+ B lymphocytes and received intravenous injections of 1 mg/kg P1 or P2 moxetumomab pasudotox (n=12/group) on study Days 1, 3, and 5. Samples collected at pre-designated timepoints were analyzed for moxetumomab pasudotox serum concentration determination (electrochemiluminescence assay) and CD20+/CD22+ B lymphocyte count (flow cytometry assay). Population PK-PD modeling was performed using the software package NONMEM (Version VI, Level 2, ICON, Ellicott City, MD). The first-order conditional estimation with interaction method was employed. Potential effects of manufacturing process on moxetumomab pasudotox clearance, efficacy and potency were assessed in covariate analyses. Results: A two-compartmental model with a first-order elimination pathway well captured the PK properties of moxetumomab pasudotox following IV injections. The estimated systemic clearance was 76.3 mL/kg/h with a steady-state distribution volume of 123.5 mL/kg. A hematopoietic transit model coupled with moxetumomab pasudotox-induced cytotoxic effect on mature B lymphocyte was successfully established to characterize B lymphocyte depletion. A negative feedback to influx from precursor cells was also included to achieve the best fit. A life-span of 51.2 days was estimated for mature B lymphocytes in cynomolgus monkeys. The serum moxetumomab pasudotox concentration that leads to half of the maximum cell killing activity (EC50) was estimated at 38.2 ng/mL. Consistent with prior bioequivalence assessment the manufacturing process change had no impact on the systemic clearance of moxetumomab pasudotox in cynomolgus monkeys. In addition, the covariate analysis didn’t reveal any significant impact of P1 or P2 on CD22+ B-cell depleting activities of moxetumomab pasudotox. Conclusions: The PK of moxetumomab pasudotox and depletion of CD22+ B cells were adequately described by the population PK-PD model. Covariate analysis demonstrated that manufacturing process had no significant effect on moxetumomab pasudotox PK or PD. Results from this study supported further clinical investigation of moxetumomab pasudotox using the new Process 2 material Population Pharmacokinetic-Pharmacodynamic Modeling to Support Biocomparability Assessment of Moxetumomab Pasudotox in Cynomolgus Monkey Zhenling Yao, Lorin Roskos, Mikhail Zusmanovich, Meina Liang, Theresa LaVallee, Bing Wang MedImmune LLC, Hayward CA and Gaithersburg MD ACoP Annual Meeting; San Diego; Apr 3-6, 2011 ABSTRACT INTRODUCTION CD22 An Ig superfamily B-lymphocyte- specific adhesion receptor Upon ligand binding CD22 is internalized and targeted to lysosomal compartment for degradation (no recycling) Moxetumomab Pasudotox (CAT-8015) A recombinant immunotoxin composed of an anti-CD22 immunoglobulin variable domain and a truncated form of Pseudomonas exotoxin 38 (PE38) Noncompartmental analysis and statistical analysis for biocomparability assessment was performed using the bioequivalence tool in WinNonlin Professional (version 5.2). Mechanistic PKPD model was developed to Characterize PKPD relationship of moxetumomab pasudotox Use process change as covariate to assess impact on PK and response on lymphocyte depletion PK Assay An electrochemiluminescence (ECL) assay was developed and validated on a Meso Scale Discovery® (MSD) platform. (LLOQ=7.8 ng/mL) Flow Cytometry Developed and qualified to assess the relative percentages of CD20+ and CD22+ cells. Total lymphocyte counts determined using a hematology analyzer. Immunogenicity Assay The presence of ADA was detected using a validated ECL assay. The assay is sensitive (LOD 41 ng/mL) and drug-tolerant (0.5 ug/mL) Pre-existing anti-drug antibodies screened to minimize PK variability Animals randomized to 2 treatment groups based on CD22 levels Three intravenous (IV) doses at 1mg/kg on Days 1, 3 and 5 Samples were collected for PK, flow cytometry and immunogenicity assessment METHODS RESULTS CONCLUSION In vivo Comparability Study Significant CMC process changes occurred during the clinical development of moxetumomab pasudotox An in vivo PKPD study is required to demonstrate biocomparability (bioequivalence) of the two clinical materials Objective: Assess the pharmacokinetic (PK) and pharmacodynamic (PD) biocomparability of Process 1 and Process 2 materials in male cynomolgus monkeys following a single-cycle intravenous treatment Study Design Bioanalytical Data Analysis Figure 1: PKPD model of moxetumomab pasudotox Figure 2: PK profiles of moxetumomab pasudotox in male monkeys following first dose of Process 1(A) or Process 2(B) clinical material Figure 4: Basic GOF plots for final PKPD model Figure 5: Visual predictive check (A) PK, 1 st dose; (B) PK, 2 nd dose; (C) PK, 3 rd dose; (D) CD20+ lymphocyte Figure 3: Baseline-normalized counts of CD20+ (A) or CD22+ (B) lymphocytes Process 1 Process 2 Process 1 Process 2 Hematopoietic transit PD model Cytotoxic effect on mature CD22+ B cells No cytotoxic effect on precursor cells Negative feedback to influx from precursor cells Pop PKPD was performed using NONMEM (version 7.1.0) FOCE INTER VPC and Bootstrap performed NCA and Biocomparability Assessment Bi-phasic PK disposition following IV dosing Most PK observations fell below LLOQ 12 hours after dosing Cell depletion observed for both CD20+ and CD22+ cells; Recovered at d21 Pop PKPD Modeling Estimated lifespan of mature B cells was 51.2 days in monkeys The maximum B cell destruction by moxetumomab pasudotox (E max ) corresponds to a mean B cell survival time of 18 hr when serum concentration greatly exceeds EC 50 Covariate analysis demonstrated clinical material change has no impact on PK or PD of moxetumomab pasudotox A GLP PKPD study was conducted in male cynomolgus monkeys to assess in vivo biocomparability of moxetumomab pasudotox Bioequivalence was met for Process 1 and Process 2 materials following 1 st dose A hematopoietic transit PD model was developed to characterize the lymphocyte depletion following moxetumomab pasudotox administration Covariate analysis confirmed that process change did not impact on moxetumomab pasudotox PK and response on lymphocyte depletion The study supported further clinical investigation of moxetumomab pasudotox using the new clinical material ACKNOWLEDGEMENT Samuel S. Chuang and Stephanie Fraser (Charles River Laboratories, Reno, NV) Inna Vainshtein, Rozanne Lee, Amy Schneider, Feng Jin, Kamille O’Connor, Bettina Kasprzyk, Laurie Iciek, Jan Popp, Steve Yim and Chris Forespring (MedImmune LLC) Bioequivalence assessment was conducted based on the exposure following the 1 st dose The 90% confidence intervals of geometric mean ratios were within the [0.8,1.25] interval for C max, AUC last and AUC inf. Process 1 and Process 2 materials are bioequivalent in monkeys
Your consent to our cookies if you continue to use this website.